Curis | CRIS - Net Income


Curis reported $-24.2M in Net Income for its fiscal quarter ending in March of 2026.





Net Income Change Date
Alaunos Therapeutics USD -1.01M 153K Mar/2026
Amgen USD 2.38B 556M Jun/2026
AstraZeneca USD 2.51B 573M Jun/2026
Bayer EUR 219M 2.54B Jun/2026
Bristol-Myers Squibb USD 3.32B 640M Jun/2026
CSL USD 401M 96.5M Dec/2025
Curis USD -24.2M 43.56M Mar/2026
Eli Lilly USD 7.1B 301M Jun/2026
Exelixis USD 212.05M 1.58M Jun/2026
Gilead Sciences USD -10.5B 12.52B Jun/2026
GlaxoSmithKline GBP 435M 1.3B Jun/2026
Incyte USD 585.6M 282.27M Jun/2026
Merck USD -1.34B 2.9B Jun/2026
Novartis USD 3.26B 108M Jun/2026
Pfizer USD -248M 2.94B Jun/2026
Roche Holding CHF 6.87B 1.4B Jun/2026
Sanofi EUR 343M 1.27B Jun/2026
Takeda JPY 113.2B 137.52B Jun/2026
TG Therapeutics USD 7.78M 12M Jun/2026
Verastem USD -36.59M 3.68M Mar/2026